IHE - iShares U.S. Pharmaceuticals ETF
| Previous Close | 161.01 |
| Open | 161.67 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1400 |
| Day's Range | 160.72 - 161.67 |
| 52 Week Range | 136.66 - 165.70 |
| Volume | 3,392 |
| Avg. Volume | 16,834 |
| Net Assets | 350.56M |
| NAV | 161.19 |
| PE Ratio (TTM) | N/A |
| Yield | 1.40% |
| YTD Daily Total Return | 0.67% |
| Beta (5Y Monthly) | 1.00 |
| Expense Ratio (net) | 0.42% |
| Inception Date | 2006-05-01 |
- Zacks
Pharma ETFs Gain on Healthy Q4 Earnings
Strong results led to solid trading in pharma ETFs over the past week.
- Zacks
4 Sector ETFs Sizzling With Solid Buybacks
Inside the sectors that have seen strong share buybacks in the past 10 years.
- Zacks
Pharma ETFs Set to Benefit Post Strong Q3 Earnings
Robust results led to solid trading in pharma ETFs in a month.
- Zacks
JNJ Beats, Ups View: Healthcare ETFs to Buy
Johnson & Johnson continued its long streak of earnings beat and outpaced revenue estimates. It also raised its guidance for the full year.
- ETF Trends
Johnson & Johnson, UnitedHealth Give Healthcare ETFs a Much Needed Bolster Shot
Healthcare stocks and sector-related exchange traded funds found support from a strong start to the earnings season after UnitedHealth Group (NYSE: UNH) and Johnson & Johnson (NYSE: JNJ) provided a much ...
- ETF Trends
Potential Peanut Allergy Treatment Gives Pharma Company A Boost
Most people are aware that peanuts can cause a severe, potentially life-threatening allergic reactions, which can be unpredictable, and even minuscule amounts of peanut can cause a disaster. Aimmune Therapeutics Inc.’s tortuous path to get its first allergy treatment approved by U.S. regulators faces its next chapter when a panel of advisers to the Food and Drug Administration meets in a couple of days. The advisory committee’s discussion and recommendation on Sept. 13 may guide investors looking for details about the potential commercial success of a product designed to protect patients with peanut allergies.
- Yahoo Finance
Stock market news: August 27, 2019
U.S. stocks swung into negative territory, ending Tuesday’s session lower after a closely watched portion of the Treasury yield curve inverted further and stoked fears of a recession.
- ETF Trends
8 ETFs to Capture Opportunities in Healthcare Sector
Institutional investors and hedge funds have shifted away from technology names as the U.S.-China trade war extends and picked up battered healthcare names. Retail investors can also gain exposure to the ...
- Zacks
Pharma Q2 Earnings Growth Highest: Time to Buy ETFs?
Despite robust results, pharma ETFs have been trending downward in a month.
- Zacks
Healthcare ETFs in Focus on JNJ's Q2 Earnings Beat
Johnson & Johnson beat the second-quarter earnings and revenue estimates but warned on competition from generics and biosimilars that could impact its third-quarter results.
- ETF Trends
4 Hot Pharmaceutical ETFs
Pharmaceutical ETFs invest in stocks of companies that are involved in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. With Johnson and Johnson continuing ...
- Zacks
AbbVie to Buy Allergan: Prescribed ETFs
AbbVie has agreed to buy Botox-maker Allergan for $63 billion in a cash-and-stock deal. The news has put the spotlight on a number of healthcare ETFs.
- ETF Trends
AbbVie, Allergan Deal Puts Spotlight on Pharmaceutical ETFs
Pharmaceutical sector-specific exchange traded funds showed mixed results Tuesday after AbbVie (NYSE: ABBV) agreed to acquire Allergan (NYSE: AGN) for $63 billion. Among the largest pharma-specific ETFs, ...
- ETF Trends
Legal Troubles Beset Pharmaceutical Sector ETFs
Pharmaceutical ETFs may be in trouble with legal troubles looming over the industry. The drugmaker segment recently sold-off after an amended civil antitrust complaint brought by more than 40 state attorneys ...
- Zacks
Pharma ETFs Down Despite Solid Q1 Results
Despite such robust results, pharma ETFs have been trending downward in a month.
- ETF Trends
Pharmaceutical ETFs Catch Healthcare Contagion
The retreat in healthcare stocks is bleeding over, with areas like pharmaceutical sector exchange traded funds being dragged down by association. The iShares U.S. Pharmaceuticals ETF (IHE) continued its downward spiral Thursday, falling 0.4%. “Clearly, huge stock impacts to HCA and managed care can’t be ignored and ‘collateral damage’ to sub-sectors like biopharma in the following days are reflective of a view that mutual funds are drawing down and souring” on health care, Jefferies analyst Michael Yee wrote in a note, according to Bloomberg.
- Zacks
JNJ Beats, Ups Sales Growth View: Healthcare ETFs in Focus
Johnson & Johnson continued its long streak of earnings beat and also outpaced revenue estimates. Though it raised the guidance for full-year sales growth, it tightened the earnings per share forecast.
- ETF Trends
4 ETFs to Consider with Big Pharma on the Senate’s Hot Seat
Big pharmaceutical companies were on the hot seat at Capitol Hill today with CVS Health, Cigna, Prime Therapeutics, Humana, and UnitedHealthcare's OptumRx testifying before the Senate Finance Committee on the rising cost of prescription drugs. Among the topics discussed included rebates paid by drug makers contributing to the high costs and the drug industry's pursuit of profits--all to shift the blame from the pharmaceutical companies to the drug makers. U.S. President Donald Trump has already lambasted the pharmaceutical industry for the rising costs associated with prescription drugs.
- Zacks
Why These Pharma ETFs Rallied on Thursday
A few pharma ETFs hit a one-month high on Feb 28. Why?
